AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01129024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lusutrombopag
Description: tablet
Study NCT03541915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mg (magnesium sulfate)
Description: 20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
Study NCT03541915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (saline)
Description: The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
Study NCT03442868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency rTMS
Description: Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex (M1), supplementary motor area (SMA) and dorsolateral prefrontal cortex (DLPFC) at different sessions. Walking performance is evaluated before and after the brain stimulation.
Study NCT02279407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching to Omega-3 carboxylic acids (olive oil)
Study NCT02279407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acids
Description: 4 g administered as 4 x 1 g capsules
Study NCT02279407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg administered as 10 mg tablet
Study NCT02279407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to dapagliflozin 10 mg
Study NCT04617431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health application and social media
Description: The intervention involved reminding the intervention group to upload their dietary diary every day. The researchers were trained by a dietitian and provided suggestions about diet and exercise to the intervention group. LINE  is a mobile app operated by LINE Corporation. All users can use texts, images, video, and audio for contact at any time. A LINE group was created to deliver medical knowledge of diet and exercise. Each of the messages were guided by a diet manual for kidney disease (edited by Department of Dietetics, National Taiwan University Hospital Yunlin Branch). The intervention group also asked questions about CKD management, and a teleconsultation of health information was provided. A daily target of 7,500 steps was set and used to emphasize the correct concepts about exercise. Participants were inspired in the intervention group if someone achieved the target number of steps.
Study NCT01868919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Parenting Program
Description: Level 3 or 4 of Triple P
Study NCT01843647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
Study NCT01843647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression.
Study NCT02827656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl
Description: luteal support as described and vaginal progesterone 200 mg 3 times a day
Study NCT02827656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG luteal support
Description: luteal support as described and vaginal progesterone 200 mg 3 times a day
Study NCT02636140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light
Description: A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
Study NCT03609593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.
Study NCT03609593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax: 12 cycles~Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows:~* Cycle 4 days 1-7 (Week 1): 20 mg once daily~* Cycle 4 days 8-14 (Week 2): 50 mg once daily~* Cycle 4 days 15-21 (Week 3): 100 mg once daily~* Cycle 4 days 22-28 (Week 4): 200 mg once daily~* Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration.
Study NCT03609593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).
Study NCT03513848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retimer
Description: The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (\~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
Study NCT03513848 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Retimer placebo
Description: The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
Study NCT03160547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Protein/Amino Acid Group
Description: Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
Study NCT03160547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher Protein/Amino Acid Group
Description: Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
Study NCT04652414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 50mg will be administered enterally for 7 days.
Study NCT04652414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a matching placebo to prednisone.
Study NCT03010436 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Benralizumab
Description: one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
Study NCT03893253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Booster Teaching
Description: The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
Study NCT03893253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Booster Teaching
Description: The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
Study NCT02293109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Given IV
Study NCT02293109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT02293109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT02293109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT02293109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT02293109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT02293109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT02293109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or PO
Study NCT02293109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV
Study NCT02293109 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT02293109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03026387 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological battery tests
Description: The neuropsychological battery tests is composed with: Continuous Performance Test, Iowa Gambling Test, Verbal fluency (animals), Emotional stroop, Self-injury implicit association test and N-back test.~The neuropsychological battery assesses domains heavily involved in suicidal behavior: impulsivity, affective dysregulation, alterations in decision-making (risky choices), selective attention,verbal fluidity and working memory.
Study NCT01244620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxentan
Description: sitaxsentan 100 mg QD for 6 days
Study NCT01244620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: tadalafil 40 mg QD for 6 days
Study NCT01244620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxsentan
Description: sitaxsentan 100 mg QD for 6 days
Study NCT01244620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitaxsentan
Description: sitaxentan 100 mg QD for 6 days
Study NCT01244620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: sildenafil 20 mg TID for 6 days
Study NCT02773134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brace Group
Description: All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~All patients will complete the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (preoperatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care.
Study NCT02773134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~Bracing will not be prescribed postoperatively for this group. All patients will the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (pre-operatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care.
Study NCT00725517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin
Description: Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
Study NCT01959750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem-based sessions
Description: weekly sessions for small groups of caregivers, led by two psychologists acting as moderators and using a systemic approach, as suggested in other peer-support groups using a problem-based method
Study NCT03199547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: The women will be randomized to receive a single dose of Azithromycin or Placebo
Study NCT03199547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The women will be randomized to receive a single dose of Azithromycin or Placebo
Study NCT01813175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular non-hydrolysed cow's milk I
Description: Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
Study NCT03815279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
Study NCT03815279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide PO once daily on days 1-21 of a 28 day cycle
Study NCT03815279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered weekly
Study NCT02498847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE
Description: Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~* What is Osteoarthritis?~* Information about treatments~* Exercise~* Sleep hygiene~* Relaxation~* Pleasant Activity Scheduling~* Goal setting~* Problem Solving~* Pacing~* Communication
Study NCT02640599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation + Aerobic Exercise
Description: Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
Study NCT02640599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation
Description: The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
Study NCT01428921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory based education and brief motivation interview
Description: * Standard education programme as described above,~* Plus~  1. Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~ 2. Follow-up phone call would be arranged within 1 week after using CPAP.~ 3. Video, slides and booklets would be used as education media.
Study NCT02468193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osilodrostat
Description: Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.
Study NCT00775164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: 15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
Study NCT00775164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin XR; 1000 mg once daily
Study NCT01306981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
Study NCT01306981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subconjunctival injection of 0.05ml saline 0.9% w/v
Study NCT04032977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PN40082
Description: To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
Study NCT04032977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PN40082
Description: To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
Study NCT04032977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Silk
Description: To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
Study NCT04032977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Silk
Description: To provide a 1-point improvement in the lip fullness grading scale score of subjects with very thin or thin lips or subjects with Fitzpatrick IV, V or VI to improve the LFGS score by 1 for 1 or both lips
Study NCT02159950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02159950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Given IV
Study NCT02159950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: Given PO
Study NCT00678639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation unit care, coupled with cardiac MRI
Description: After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
Study NCT00974740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
Study NCT00974740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atorvastatin matching placebo
Description: atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
Study NCT03423680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abilify 2, 5, 10, 15mg (Tablet)
Description: Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
Study NCT03423680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Abilify 2, 5, 10, 15mg (Tablet)
Description: Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
Study NCT03125473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN Oral Vaccine
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.
Study NCT02729714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suvorexant
Description: 10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
Study NCT02729714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: 10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
Study NCT02729714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
Study NCT02729714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
Study NCT06074289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family connections program
Description: Caregivers meet weekly for 90 minute sessions led by two trained psychologists. The program includes six modules: 1. Introduction, 2. Family Education, 3. Relationship Mindfulness Skills, 4. Family Environment Skills, 5. Validation Skills, 6. Problem Management Skills.
Study NCT02909907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Description: Botulinum injections into dominant upper extremity using protocol outlined above.
Study NCT02909907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above
Study NCT01888822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy
Study NCT01888822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin-sulbactam
Description: Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy